[1]薛会朝,王　雷,李　建,等.乳腺癌干细胞及其分化细胞中雌激素受体、孕激素受体和人类表皮生长因子受体2的表达[J].新乡医学院学报,2017,34(5):361-364.[doi:10.7683/xxyxyxb.2017.05.004]
　XUE Hui-chao,WANG Lei,LI Jian,et al.Expression of estrogen receptor，progesterone receptor and human epidermal growth factor receptor 2 in breast cancer stem cells and their differentiated cells[J].Journal of Xinxiang Medical University,2017,34(5):361-364.[doi:10.7683/xxyxyxb.2017.05.004]
点击复制

乳腺癌干细胞及其分化细胞中雌激素受体、孕激素受体和人类表皮生长因子受体2的表达
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
34
期数:
2017年5
页码:
361-364
栏目:
基础研究
出版日期:
2017-05-05

文章信息/Info

Title:
Expression of estrogen receptor，progesterone receptor and human epidermal growth factor receptor 2 in breast cancer stem cells and their differentiated cells
作者:
薛会朝; 王　雷; 李　建; 王　迎; 王国戗; 郭长磊
（新乡医学院第一附属医院普外科，河南　卫辉　453100）
Author(s):
XUE Hui-chao; WANG Lei; LI Jian; WANG Ying; WANG Guo-qiang; GUO Chang-lei
（Department of General Surgery，the First Affiliated Hospital of Xinxiang Medical University，Xinxiang 453100，Henan Province，China）
关键词:
乳腺癌; 肿瘤干细胞; 雌激素受体; 孕激素受体; 人类表皮生长因子受体2
Keywords:
breast cancer; tumor stem cells; estrogen receptor; progesterone receptor; human epidermal growth factor receptor 2
分类号:
R737.9
DOI:
10.7683/xxyxyxb.2017.05.004
文献标志码:
A
摘要:
目的　探讨乳腺癌干细胞及其分化细胞中雌激素受体（ER）、孕激素受体（PR）和人类表皮生长因子受体2（HER-2）的表达及意义。方法　选取2016年1月至2016年10月新乡医学院第一附属医院标本室保存的新鲜乳腺癌标本35例，制备单细胞悬液，利用免疫磁珠分选法进行细胞分选，分选出乳腺癌干细胞（CD44+CD24-/low细胞）和分化细胞（CD44-CD24-细胞），利用Envision二步法检测乳腺癌干细胞及其分化细胞中ER、PR、HER-2的表达。结果　同一患者的乳腺癌干细胞与分化细胞的ER、PR、HER-2表达呈现出3种情况：（1）乳腺癌干细胞阴性表达，分化细胞阳性表达；（2）乳腺癌干细胞阳性表达，分化细胞阳性表达；（3）乳腺癌干细胞阴性表达，分化细胞阴性表达。分化细胞中ER、PR及HER-2阳性表达率显著高于乳腺癌干细胞（P<0.05）。乳腺癌干细胞及其分化细胞共有4种表型，分别为SR+HER-2-、SR+HER-2+、SR-HER-2+和SR-HER-2-，其中，SR表示ER和（或）PR。乳腺癌干细胞的SR-HER-2-表型比例最大，分化细胞的SR+HER-2-表型比例最大；分化细胞的SR+HER-2-、SR+HER-2+表型比例显著高于乳腺癌干细胞（P<0.05），分化细胞的SR-HER-2-表型比例显著低于乳腺癌干细胞（P<0.05），但分化细胞与乳腺癌干细胞的SR-HER-2+表型比例比较差异无统计学意义（P>0.05）。结论　乳腺癌干细胞中ER、PR、HER-2阳性表达较低，随着乳腺癌干细胞的不断分化，阳性表达逐渐增加。
Abstract:
Objective　To investigate the significance of the expression of estrogen receptor（ER），progesterone receptor（PR）and human epidermal growth factor receptor 2（HER-2）in breast cancer stem cells and their differentiated cells.Methods　Thirty-five fresh breast cancer specimens were selected from January 2016 to October 2016 in the First Affiliated Hospital of Xinxiang Medical University.The tissue specimens were used to make single cell suspensions.The breast cancer stem cells（CD44+CD24-/low cells）and the differentiated cells（CD44-CD24-cells）were sorted by immunomagnetic beads method.The expressions of ER，PR and HER-2 in breast cancer stem cells and their differentiated cells were detected by Envision two-step method.Results　The expressions of ER，PR and HER-2 in breast cancer stem cells and their differentiated cells of the same patient showed three cases：（1）negative expression in breast cancer stem cells，and positive expression in differentiated cells；（2）positive expression in breast cancer stem cells and their differentiated cells；（3）negative expression in breast cancer stem cells and their differentiated cells.The positive expression rates of ER，PR and HER-2 in differentiated cells were significantly higher than those in breast cancer stem cells（P<0.05）.There were four phenotypes including SR+HER-2-，SR+HER-2+，SR-HER-2+ and SR-HER-2- in breast cancer stem cells and their differentiated cells（SR represents ER and/or PR）.The proportion of SR-HER-2- phenotype was the largest in breast cancer stem cells.The proportion of SR+HER-2- phenotype was the largest in the differentiated cells.The proportions of SR+HER-2- and SR+HER-2+ phenotypes in the differentiated cells were significantly higher than those in breast cancer stem cells（P<0.05）.The proportion of SR-HER-2- phenotype in the differentiated cells was significantly lower than that in breast cancer stem cells（P<0.05）.There was no significant difference in the proportion of SR-HER-2+ phenotype between breast cancer stem cells and their differentiated cells（P>0.05）.Conclusion　The positive expression of ER，PR and HER-2 was lower in breast cancer stem cells.With the differentiation of breast cancer stem cells，the positive expression of ER，PR and HER-2 increase gradually.

参考文献/References:

［1］　MORIMOTO K，KIM S J，TANEI T，et al.Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor，positive human epidermal growth factor receptor type 2，and high Ki67 expression［J］.Cancer Sci，2009，100（6）：1062-1068.
［2］　王慧，康欣梅.乳腺癌干细胞标志物及乳腺癌干细胞治疗策略［J］.新乡医学院学报，2015，32（10）：964-967.
［3］　王立斌，何亚琴，吴立刚，等.人乳腺肿瘤干细胞分离培养及鉴定［J］.细胞与分子免疫学杂志，2012，28（12）：1261-1264.
［4］　张慧明，葛智成，王子函，等.单一激素受体阳性浸润性Luminal A亚型乳腺癌的临床分析［J］.临床和实验医学杂志，2014，13（5）：343-346.
［5］　刘桂超，邬蒙.三阴乳腺癌与激素受体阴性、HER-2阳性乳腺癌的临床病理特征及预后对比分析［J］.肿瘤预防与治疗，2010，23（1）：32-35.
［6］　ADAMCZYK A，NIEMIEC J A，AMBICKA A，et al.CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy［J］.J Mol Histol，2014，45（1）：35-45.
［7］　王淑莲，李晔雄，宋永文，等.激素受体和人表皮生长因子受体2的表达与改良根治术后淋巴结阳性乳腺癌患者预后的关系［J］.中华肿瘤杂志，2010，32（7）：520-525.
［8］　HASHIMOTO K，SHIMIZU C，TSUDA H，et al.Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome［J］.Oncology，2012，82（3）：168-174.
［9］　RHODES L V，MUIR S E，ELLIOTT S，et al.Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence［J］.Breast Cancer Res Treat，2010，121（2）：293-300.
［10］　刘珊，张巍，牛昀，等.乳腺癌干细胞与激素调控的研究进展［J］.中华医学杂志，2014，94（4）：310-312.
［11］　刘珊，张巍，刘夏，等.雄激素受体阳性乳腺癌干细胞的富集及其特性鉴定［J］.中华实验外科杂志，2014，31（1）：67-69.
［12］　GINESTIER C，HUR M H，CHARAFE-JAUFFRET E，et al.ALDH1 is a marker of normal and malignant human mammary stem ceUs and a predictor of poor clinical outcome［J］.Stem Cells，2007，1（5）：555-567.
［13］　SIMOES B M，VIVANCO M D.Cancer stem cells in the humanmammary gland and regulation of their differentiation by estrogen［J］.Future Oncol，2011，7（8）：995-1006.
［14］　邵军，潘翠萍，王明伟，等.乙醛脱氢酶1和雌激素受体在乳腺癌原发灶与复发转移灶之间的表达差异［J］.解剖学报，2013，44（2）：224-228.
［15］　玄东春，金文彪，崔海，等.Her-2与ALDH1在乳腺癌中表达与相关性研究［J］.现代仪器，2012，18（6）：26-29.
［16］　杨国华，薛芳沁，陈晓耕，等.不同分子分型乳腺癌干细胞MDR1表达的研究［J］.南方医科大学学报，2012，32（11）：1636-1638.
［17］　桑晶，孙勇，韩玉贞，等.乳腺癌干细胞激素受体与HER-2表达生物学意义的分析［J］.中华肿瘤防治杂志，2013，20（12）：926-929.

相似文献/References:

[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 ． 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王　乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
　YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor，progestin recetor，Ki-67 antigen，and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(5):125.[doi:10.7683/xxyxyxb.2017.02.012]

更新日期/Last Update: 2017-05-05